



61

AF 1644

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/688,017
Filing Date	October 13, 2000
First Named Inventor	Unger, Marc
Art Unit	1644
Examiner Name	DeCloux, Amy M.
Attorney Docket Number	020054-001110US

Total Number of Pages in This Submission

## ENCLOSURES (Check all that apply)

- |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <input type="checkbox"/> Fee Transmittal Form<br><input type="checkbox"/> Fee Attached<br><input type="checkbox"/> Amendment/Reply<br><input type="checkbox"/> After Final<br><input type="checkbox"/> Affidavits/declaration(s)<br><input type="checkbox"/> Extension of Time Request<br><input type="checkbox"/> Express Abandonment Request<br><input checked="" type="checkbox"/> Information Disclosure Statement<br><input type="checkbox"/> Certified Copy of Priority Document(s)<br><input type="checkbox"/> Response to Missing Parts/ Incomplete Application<br><input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Drawing(s)<br><input type="checkbox"/> Licensing-related Papers<br><input type="checkbox"/> Petition<br><input type="checkbox"/> Petition to Convert to a Provisional Application<br><input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address<br><input type="checkbox"/> Terminal Disclaimer<br><input type="checkbox"/> Request for Refund<br><input type="checkbox"/> CD, Number of CD(s) | <input type="checkbox"/> After Allowance Communication to Group<br><input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences<br><input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)<br><input type="checkbox"/> Proprietary Information<br><input type="checkbox"/> Status Letter<br><input checked="" type="checkbox"/> Other Enclosure (please identify below)<br>Return Postcard, copy of fifty-seven (57) cited references |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

RECEIVED

FEB 03 2004

TECH CENTER 1000/2900

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Scott L. Ausenhus	Reg. No. 42,271
Signature		
Date	January 28, 2004	


## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Nicole M. Wartell		
Signature		Date	January 28, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.




I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT  
Attorney Docket No.: 020054-001110US

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

On January 28, 2004

TOWNSEND and TOWNSEND and CREW LLP

By:   
Nicole M. Burke

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

FEB 08 2004

In re application of:

LU et al.

Application No.: 09/688,017

Filed: October 13, 2000

For: MOLECULAR INTERACTIONS  
IN HEMATOPOIETIC CELLS

Examiner: DeCloux, Amy M.

Art Unit: 1644

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

TECH CENTER 1600/2900

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

Applicants wish to make the Examiner aware of the following co-pending patent applications:

1. U.S. Patent App. No. 09/722,069, filed 11/24/2000, Attorney Docket No. 020054-001122US; and
2. U.S. Patent App. No. 09/724,553, filed 11/28/2000, Attorney Docket No. 020054-001130US.

To comply with 37 CFR §1.98(a)(2)(iii), the specifications, claims and drawings for the above applications are enclosed.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus  
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 303-571-4000  
Fax: 303-571-4321  
SLA:nmb



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 5

**Complete if Known**

Application Number	09/688,017
Filing Date	October 13, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy M.
Attorney Docket Number	020054-001110US

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	US-5,632,994	05/27/97	Reed et al.	
	A2	US-5,747,245	05/05/98	Reed et al.	
	A3	US-5,876,939	03/02/99	Reed et al.	
	A4	U.S. Application No. 07/724,553		Lu et al.	
	A5	U.S. Application No. 09/722,069		Lu et al.	

RECEIVED

FEB 03 2004

TECH CENTER 1003/2000

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	B1	PCT	WO 98/05347	A1	02-12-1998			<input type="checkbox"/>
	B2	PCT	WO 98/23781	A1	06-04-1998			<input type="checkbox"/>
	B3	PCT	WO 98/40407	A1	09-17-1998			<input type="checkbox"/>
	B4	PCT	WO 99/03974	A1	01-28-1999			<input type="checkbox"/>
	B5	PCT	WO 99/07846	A1	02-18-1999			<input type="checkbox"/>
	B6	PCT	WO 00/15794	A1	03-23-2000			<input type="checkbox"/>
	B7	PCT	WO 00/31124	A2	06-02-2000			<input type="checkbox"/>
	B8	PCT	WO 00/48002	A1	08-17-2000			<input type="checkbox"/>
	B9	PCT	WO 00/69896	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
	B10	PCT	WO 00/69897	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
	B11	PCT	WO 00/69898	A2	11-23-2000	Arbor Vita Corp		<input type="checkbox"/>
	B12	PCT	WO 02/42422	A2	05-30-2002	Arbor Vita Corp		<input type="checkbox"/>

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2

of 5

**Complete if Known**

Application Number	09/688,017
Filing Date	October 13, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy M.
Attorney Docket Number	020054-001110US

**NON PATENT LITERATURE DOCUMENTS**


Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1 ✓	Altin, J. and Sloan, E. "The role of CD45 and CD45-associated molecules in T cell activation" <i>Immunology and Cell Biology</i> , 1997, pp. 430-445, Vol. 75.	
	C2 ✓	Bals, R. et al. "Augmentation of Innate Host Defense by Expression of a Cathelicidin Antimicrobial Peptide", <i>Infection and Immunity</i> , November 1999, pp. 6084-6089, Vol. 67, No. 11.	
	C3 ✓	Barclay, A., et al., "The Leukocyte Antigen Factsbook", <i>Harcourt Brace &amp; Company</i> , page 363, (1997).	
	C4 ✓	Bruyns, E. et al. "Identification of the Sites of Interaction between Lymphocyte Phosphatase-associated Phosphoprotein (LPAP) and CD45", <i>Journal of Biological Chemistry</i> , December 29, 1996, pp. 31372-31376, Vol. 270, No. 52, U.S.A.	
	C5 ✓	Cherukuri, A. et al. "Floating the raft hypothesis: lipid rafts play a role in immune cell activation", <i>Immunity</i> , June 2001, pp.657-660, Vol. 14, Cell Press.	
	C6 ✓	Ding, I. Et al., "Biochemical and Functional Analysis of Mice Deficient in Expression of the CD45-Associated Phosphoprotein LPAP", <i>European Journal of Immunology</i> , 29(12):3956-61 (1999).	
	C7 ✓	Doyle, D. A., et al., "Crystal structures of a complexed and peptide-free membrane protein-binding domain: molecular basis of peptide recognition by PDZ", <i>Cell</i> , 85(7):1067-76, (1996).	
	C8 ✓	Faulkner, G. et al. "A New Z-band Alternatively Spliced PDZ-motif Protein." <i>The Journal of Cell Biology</i> , July 26, 1999; pp. 465-475, Vol. 146, No. 2.	
	C9 ✓	Gardioli, D. et al. "Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation", <i>Oncogene</i> , 18(40):5487-5496, (1999).	
	C10 ✓	Gee, S.H., et al., "Cyclic Peptides as Non-carboxyl-terminal Ligands of Syntrophin PDZ Domains", <i>The Journal of Biological Chemistry</i> , 273(34):21980-21987, (1998).	
	C11 ✓	Hanada, T., et al., "Human Homologue of the Drosophila Discs Large Tumor Suppressor Binds to p56 <sup>lck</sup> Tyrosine Kinase and Shaker Type Kv1.3 Potassium Channel in T. Lymphocytes", <i>The Journal of Biological Chemistry</i> , 272(43):26899-26904, (1997).	
	C12 ✓	Kiyono, T. et al. "Binding of high-risk human papillomavirus E6 oncoproteins to the human homologue of the Drosophila discs large tumor suppressor protein", <i>Proc. Natl. Acad. Sci.</i> , October 1997, pp. 11612-11616, Vol. 94, U.S.A.	
	C13 ✓	Kobayashi, I., et al., "Identification of an Autoimmune Enteropathy-related 75-kilodalton Antigen", <i>Gastroenterology</i> , October 1999, pp. 823-830, Vol. 117, No. 4.	

Examiner  
SignatureDate  
Considered

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.  
47111948 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 3 of 5

**Complete if Known**

Application Number	09/688,017
Filing Date	October 13, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy M.
Attorney Docket Number	020054-001110US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C14	Maekawa, K., et al., "Association of Protein-Tyrosine Phosphatase PTP-BAS with the Transcription-factor-inhibitory Protein IxB $\alpha$ Through Interaction Between the PDZ1 Domain and Ankyrin Repeats", <i>Biochemical Journal</i> , 337(2):179-187, (1999).	
	C15	McKusick, Victor A.; OMIM Database entry entitled, '147138 Fc Fragment of IgE, High Affinity I, Receptor for, Beta Subunit; FCER1B', www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?147138, 08/27/1992.	
	C16	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain", <i>DNA Research</i> , 1996, pp. 321-329, Vol. 3.	
	C17	Nagase, T. et al. "Prediction of the Coding Sequence of Unidentified Human Genes. V1. The Coding Sequences of 80 New Genes (KIAA0201-KIAA0280) Deduced by Analysis of cDNA Clones from Cell Line KG-1 and Brain (Supplement)", <i>DNA Research</i> , 1996, pp. 341-354, Vol. 3, Supplement.	
	C18	Nishihara, H. et al. "Non-adherent cell-specific expression of DOCK2, a member of the human CDM-family proteins", <i>Biochimica et Biophysica Acta</i> , 1999, pp. 179-187, Elsevier Publishing.	
	C19	Nishihara, H. "Analysis of Hematopoietic Cell Specific Protein, M-DOCK", <i>Hokkaido Igaku Zasshi</i> , March 1999, p. 157-166, Vol. 74, No. 2.	
	C20	Patel, V. et al., "A Molecular Framework for 2-Step T Cell Signaling: Lck Src Homology 3 Mutations Discriminate Distinctly Regulated Lipid Raft Reorganization Events", <i>Journal of Immunology</i> , 166(2):754-64 (2001).	
	C21	Rasooly, Rebekah S.; OMIM Database entry entitled, "603122 Dedicator of Cytokinesis 2; Dock 2" www.ncbi.nlm.nih.gov/htbin-post/Omim/dispmm?603122, 10/12/1998.	
	C22	Reynaud, C. et al., "The PDZ Protein TIP-1 Interacts with the Rho Effector Rhotekin and Is Involved in Rho Signaling to the Serum Response Element", <i>The Journal of Biological Chemistry</i> , 275(43):33962-33968, (2000).	
	C23	Rousset, R., et al., "The C-terminus of the HTLV-1 Tax oncoprotein mediates interaction with the PDZ domain of cellular proteins" <i>Oncogene</i> , 16(5):643-54, (1998).	
	C24	Saras, J., et al., "PDZ Domains Bind Carboxy-Terminal Sequences of Target Proteins", <i>Tibs Trends in Biochemical Sciences</i> , en, Elsevier Publication, Cambridge, 21(12):455-458, (1996).	

RECEIVED

FEB 06 2004

TECH CENTER 1000/2900

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

47111948 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 4

of 5

**Complete if Known**

Application Number	09/688,017
Filing Date	October 13, 2000
First Named Inventor	Lu, Peter S., et. al.
Art Unit	1644
Examiner Name	DeCloux, Amy M.
Attorney Docket Number	020054-001110US

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C25	Schepens, J., et al., "The Neuronal Nitric Oxide Synthase PDZ Motif Binds to -G(D.E)XV Carboxy Terminal Sequences", <i>Febs Letters</i> , 409(1-2):53-56, (1997).	
	C26	Schraven, Burkhardt et al. "LPAP, a Novel 32-kDa Phosphoprotein That Interacts With CD45 in Human Lymphocytes", <i>J. Biological Chemistry</i> , Nov. 18, 1994; pp. 29102-29111, Vol. 269, No. 46.	
	C27	Shibuya, A., et al., "DNAM-1, A Novel Adhesion Molecule Involved in the Cytolytic Function of T Lymphocytes", <i>Immunity</i> , 4:573-581, (1996).	
	C28	Shibuya, A., et al., "Protein Kinase C is Involved in the Regulation of Both Signaling and Adhesion Mediated by DNAX Accessory Molecule-1 Receptor", <i>The Journal of Immunology</i> , 161:1671-1676, (1998).	
	C29	Shibuya, K., et al., "Physical and Functional Association of LFA-1 with DNAM-1 Adhesion Molecule", <i>Immunity</i> , 11:615-623, (1999).	
	C30	Suzuki, T., et al., "Tax oncoprotein of HTLV-1 binds to the human homologue of Drosophila discs large tumor suppressor protein, hDLG, and perturbs its function in cell growth control", <i>Oncogene</i> , 18(44):5967-72, (1999).	
	C31	Vallénus, T. et al. "CLP-36 PDZ-LIM Protein Associates with Nonmuscle alpha-Actinin-1 and alpha-Actinin-4." <i>The Journal of Biological Chemistry</i> , April 14, 2000; pp. 11100-11105, Vol. 275, No. 15.	
	C32	Wechsler, A. et al. "Brain Spectrin binding to the NMDA receptor is regulated by phosphorylation, calcium and calmodulin." <i>The EMBO Journal</i> , 1998, pp. 3931-3939, Vol. 17, No. 14.	
	C33	Xia, H. et al. "Actinin-associated LIM Protein: Identification of a Domain Interaction between PDZ and Spectrin-like Repeat Motifs", <i>The Journal of Cell Biology</i> , October 1997, pp. 507-515, Vol. 139, No. 2.	
	C34	Yanagisawa, J., et al., "The Molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis", <i>J. Biol. Chem.</i> , 272(13):8539-8545, (1997).	
	C35	GenBank, Accession Number AF028823, 12/01/1999	
	C36	GenBank, Accession Number BM845132, 03/06/2002	
	C37	GenBank, Accession Number CB131761, 01/29/2003	
	C38	GenBank, Accession Number CB961389, 04/28/2003	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

47111948 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/688,017		
		Filing Date	October 13, 2000		
		First Named Inventor	Lu, Peter S. , et. al.		
		Art Unit	1644		
		Examiner Name	DeCloux, Amy M.		
Page	5	of	5	Attorney Docket Number	020054-001110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C39 ✓	GenBank, Accession Number CB995033, 04/30/2003	
	C40 ✓	Genbank, Accession Number D86964, 02/07/1999	

RECEIVED

FEB 06 2004

TECH CENTER 1600/2900

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.